Principal Financial Group Inc. Increases Stock Position in Dynavax Technologies Co. (NASDAQ:DVAX)

Principal Financial Group Inc. grew its stake in shares of Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) by 3.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 596,590 shares of the biopharmaceutical company's stock after buying an additional 18,863 shares during the period. Principal Financial Group Inc. owned 0.45% of Dynavax Technologies worth $7,618,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. US Bancorp DE increased its position in shares of Dynavax Technologies by 291.4% in the third quarter. US Bancorp DE now owns 2,732 shares of the biopharmaceutical company's stock worth $30,000 after purchasing an additional 2,034 shares during the last quarter. Capital Performance Advisors LLP bought a new position in shares of Dynavax Technologies in the third quarter worth approximately $45,000. GAMMA Investing LLC increased its position in shares of Dynavax Technologies by 55.1% in the fourth quarter. GAMMA Investing LLC now owns 4,102 shares of the biopharmaceutical company's stock worth $52,000 after purchasing an additional 1,457 shares during the last quarter. Nisa Investment Advisors LLC increased its position in shares of Dynavax Technologies by 44.6% in the third quarter. Nisa Investment Advisors LLC now owns 5,441 shares of the biopharmaceutical company's stock worth $61,000 after purchasing an additional 1,679 shares during the last quarter. Finally, C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors bought a new position in Dynavax Technologies during the fourth quarter valued at approximately $71,000. 96.96% of the stock is currently owned by institutional investors.

Dynavax Technologies Trading Down 1.9 %

DVAX stock traded down $0.26 on Monday, reaching $13.53. The company's stock had a trading volume of 2,006,452 shares, compared to its average volume of 1,829,771. The business has a fifty day simple moving average of $12.89 and a two-hundred day simple moving average of $12.13. Dynavax Technologies Co. has a 12-month low of $9.74 and a 12-month high of $14.05. The firm has a market cap of $1.68 billion, a PE ratio of 75.17 and a beta of 1.32. The company has a debt-to-equity ratio of 0.33, a quick ratio of 12.34 and a current ratio of 13.23.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last announced its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported $0.05 EPS for the quarter, hitting analysts' consensus estimates of $0.05. Dynavax Technologies had a return on equity of 4.22% and a net margin of 9.85%. The company had revenue of $72.03 million during the quarter, compared to analyst estimates of $72.70 million. As a group, research analysts forecast that Dynavax Technologies Co. will post 0.32 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have commented on the stock. The Goldman Sachs Group cut shares of Dynavax Technologies from a "neutral" rating to a "sell" rating and reduced their price target for the company from $15.00 to $12.00 in a research report on Tuesday, February 11th. StockNews.com upgraded shares of Dynavax Technologies from a "hold" rating to a "buy" rating in a research report on Monday, February 24th. HC Wainwright reiterated a "buy" rating and set a $31.00 price target on shares of Dynavax Technologies in a research report on Friday, February 21st. Finally, William Blair reissued an "outperform" rating on shares of Dynavax Technologies in a research note on Friday, February 21st.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.